Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Reviva Pharmaceuticals Holdings Inc RVPH

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system and respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug... see more

Recent & Breaking News (NDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire September 6, 2022

Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights

GlobeNewswire August 15, 2022

Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline

GlobeNewswire July 27, 2022

Reviva Pharmaceuticals to Participate in the 2022 BIO International Convention

GlobeNewswire June 2, 2022

Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

GlobeNewswire May 16, 2022

Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia

GlobeNewswire May 3, 2022

Reviva Pharmaceuticals to Host Key Opinion Leader Webinar on Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders

GlobeNewswire April 26, 2022

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

GlobeNewswire March 24, 2022

Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Conference

GlobeNewswire March 22, 2022

Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences

GlobeNewswire March 18, 2022

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights

GlobeNewswire March 15, 2022

Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

GlobeNewswire February 1, 2022

Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia

GlobeNewswire January 10, 2022

Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences

GlobeNewswire December 20, 2021

Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights

GlobeNewswire November 15, 2021

Reviva Pharmaceuticals to Present at the Upcoming Benzinga Healthcare Small Cap Conference

GlobeNewswire September 15, 2021

Reviva Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 2, 2021

Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights

GlobeNewswire August 16, 2021

Reviva Added to Russell Microcap® Index

GlobeNewswire June 28, 2021